Hello. My name is Srdan Verstovsek. I am a professor of medicine in the leukemia department at MD Anderson Cancer Center in Houston, Texas. Today I want to speak to you about polycythemia vera.
This case illustrates two aspects of possible inadequate response to hydroxyurea interacting in PV. Intolerance, that is, a skin ulcer, and resistance, uncontrolled myeloproliferation and presence of systemic symptoms, despite controlled hematocrit. In about a quarter of the patients, we can find these findings, and ruxolitinib is now a new option for therapy of these patients, as it can achieve good control of blood cell count, spleen, and symptoms in patients in a second-line PV.
